470 related articles for article (PubMed ID: 33737855)
1. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
Wu Z; Cui P; Tao H; Zhang S; Ma J; Liu Z; Wang J; Qian Y; Chen S; Huang Z; Zheng X; Huang D; Hu Y
Clin Med Insights Oncol; 2021; 15():1179554921996288. PubMed ID: 33737855
[TBL] [Abstract][Full Text] [Related]
2. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Peyraud F; Italiano A
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526888
[TBL] [Abstract][Full Text] [Related]
3. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
Bound NT; Vandenberg CJ; Kartikasari AER; Plebanski M; Scott CL
Front Genet; 2022; 13():886170. PubMed ID: 36159999
[TBL] [Abstract][Full Text] [Related]
4. The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
Hunia J; Gawalski K; Szredzka A; Suskiewicz MJ; Nowis D
Front Mol Biosci; 2022; 9():1073797. PubMed ID: 36533080
[TBL] [Abstract][Full Text] [Related]
5. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.
Catalano M; Francesco Iannone L; Cosso F; Generali D; Mini E; Roviello G
Expert Opin Ther Targets; 2022 Nov; 26(11):923-936. PubMed ID: 36519314
[TBL] [Abstract][Full Text] [Related]
6. Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints.
Franzese O; Graziani G
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428727
[TBL] [Abstract][Full Text] [Related]
7. Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications.
Wanderley CWS; Correa TS; Scaranti M; Cunha FQ; Barroso-Sousa R
Front Immunol; 2022; 13():816642. PubMed ID: 35572596
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Moutafi M; Economopoulou P; Rimm D; Psyrri A
Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
[TBL] [Abstract][Full Text] [Related]
9. Advances and perspectives of PARP inhibitors.
Yi M; Dong B; Qin S; Chu Q; Wu K; Luo S
Exp Hematol Oncol; 2019; 8():29. PubMed ID: 31737426
[TBL] [Abstract][Full Text] [Related]
10. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
[No Abstract] [Full Text] [Related]
11. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
12. Recent advancements in PARP inhibitors-based targeted cancer therapy.
Zhou P; Wang J; Mishail D; Wang CY
Precis Clin Med; 2020 Sep; 3(3):187-201. PubMed ID: 32983586
[TBL] [Abstract][Full Text] [Related]
13. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
14. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
Goncalves A; Mezni E; Bertucci F
Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311
[TBL] [Abstract][Full Text] [Related]
15. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
Han Y; Li CW; Hsu JM; Hsu JL; Chan LC; Tan X; He GJ
Am J Cancer Res; 2019; 9(4):800-815. PubMed ID: 31106005
[TBL] [Abstract][Full Text] [Related]
16. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
[TBL] [Abstract][Full Text] [Related]
17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
18. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
20. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
Javle M; Curtin NJ
Ther Adv Med Oncol; 2011 Nov; 3(6):257-67. PubMed ID: 22084640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
